A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety

Kitti Szőke, Attila Czompa, I. Lekli, Péter Szabados-Fürjesi, Mihály Herczeg, Magdolna Csávás, A. Borbás, P. Herczegh, A. Tósaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ischemic heart conditions are among the main causes of sudden cardiac death worldwide. One of the strategies for avoiding myocardial infarction is the low-dose, prophylactic use of acetylsalicylic acid (ASA), an inhibitor of platelet aggregation. To avoid the gastrointestinal damage, ASA prodrugs bearing nitric oxide (NO)-donating moiety covalently conjugated to ASA have been synthesized and evaluated extensively worldwide. Herein the synthesis of a new hybrid ASA ester covalently attached to the NO donor linsidomine, an active metabolite of molsidomine (MOL) is reported. Cell viability assay and hemolysis tests were performed in H9c2 cells and rat erythrocytes, respectively. Our new compound, the ERJ-500 not affected negatively the viability of living cells in the concentration range of 100 nM to 100 μM. Using the ex vivo Langendorff method on hearts originated from female rats, compound ERJ-500 displayed a dose-dependent, outwashable vasodilative effect in coronary arteries. Vasodilation was observed on isolated working heart model as well, with elevated stroke volume in hearts treated with ERJ-500. Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion. Based on these observations it can be expected that our new hybrid ASA may contribute to new pharmacological tool in the therapy of ischemic heart conditions and associated syndromes.

Original languageEnglish
Pages (from-to)159-166
Number of pages8
JournalEuropean Journal of Pharmaceutical Sciences
Volume131
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Molsidomine
Aspirin
Nitric Oxide
Cell Survival
Nitric Oxide Donors
Platelet Aggregation Inhibitors
Sudden Cardiac Death
Prodrugs
Hemolysis
Vasodilation
Stroke Volume
Reperfusion
Coronary Vessels
Esters
Ischemia
Erythrocytes
Myocardial Infarction
Pharmacology

Keywords

  • Acetylsalicylic acid
  • Coronary flow
  • Isolated heart
  • Molsidomine
  • Nitrogen oxide liberation
  • Vasoactivity

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety. / Szőke, Kitti; Czompa, Attila; Lekli, I.; Szabados-Fürjesi, Péter; Herczeg, Mihály; Csávás, Magdolna; Borbás, A.; Herczegh, P.; Tósaki, A.

In: European Journal of Pharmaceutical Sciences, Vol. 131, 01.04.2019, p. 159-166.

Research output: Contribution to journalArticle

Szőke, Kitti ; Czompa, Attila ; Lekli, I. ; Szabados-Fürjesi, Péter ; Herczeg, Mihály ; Csávás, Magdolna ; Borbás, A. ; Herczegh, P. ; Tósaki, A. / A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety. In: European Journal of Pharmaceutical Sciences. 2019 ; Vol. 131. pp. 159-166.
@article{fbb6e64a6d69432dae0f94f5bca4a789,
title = "A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety",
abstract = "Ischemic heart conditions are among the main causes of sudden cardiac death worldwide. One of the strategies for avoiding myocardial infarction is the low-dose, prophylactic use of acetylsalicylic acid (ASA), an inhibitor of platelet aggregation. To avoid the gastrointestinal damage, ASA prodrugs bearing nitric oxide (NO)-donating moiety covalently conjugated to ASA have been synthesized and evaluated extensively worldwide. Herein the synthesis of a new hybrid ASA ester covalently attached to the NO donor linsidomine, an active metabolite of molsidomine (MOL) is reported. Cell viability assay and hemolysis tests were performed in H9c2 cells and rat erythrocytes, respectively. Our new compound, the ERJ-500 not affected negatively the viability of living cells in the concentration range of 100 nM to 100 μM. Using the ex vivo Langendorff method on hearts originated from female rats, compound ERJ-500 displayed a dose-dependent, outwashable vasodilative effect in coronary arteries. Vasodilation was observed on isolated working heart model as well, with elevated stroke volume in hearts treated with ERJ-500. Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion. Based on these observations it can be expected that our new hybrid ASA may contribute to new pharmacological tool in the therapy of ischemic heart conditions and associated syndromes.",
keywords = "Acetylsalicylic acid, Coronary flow, Isolated heart, Molsidomine, Nitrogen oxide liberation, Vasoactivity",
author = "Kitti Szőke and Attila Czompa and I. Lekli and P{\'e}ter Szabados-F{\"u}rjesi and Mih{\'a}ly Herczeg and Magdolna Cs{\'a}v{\'a}s and A. Borb{\'a}s and P. Herczegh and A. T{\'o}saki",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.ejps.2019.02.020",
language = "English",
volume = "131",
pages = "159--166",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety

AU - Szőke, Kitti

AU - Czompa, Attila

AU - Lekli, I.

AU - Szabados-Fürjesi, Péter

AU - Herczeg, Mihály

AU - Csávás, Magdolna

AU - Borbás, A.

AU - Herczegh, P.

AU - Tósaki, A.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Ischemic heart conditions are among the main causes of sudden cardiac death worldwide. One of the strategies for avoiding myocardial infarction is the low-dose, prophylactic use of acetylsalicylic acid (ASA), an inhibitor of platelet aggregation. To avoid the gastrointestinal damage, ASA prodrugs bearing nitric oxide (NO)-donating moiety covalently conjugated to ASA have been synthesized and evaluated extensively worldwide. Herein the synthesis of a new hybrid ASA ester covalently attached to the NO donor linsidomine, an active metabolite of molsidomine (MOL) is reported. Cell viability assay and hemolysis tests were performed in H9c2 cells and rat erythrocytes, respectively. Our new compound, the ERJ-500 not affected negatively the viability of living cells in the concentration range of 100 nM to 100 μM. Using the ex vivo Langendorff method on hearts originated from female rats, compound ERJ-500 displayed a dose-dependent, outwashable vasodilative effect in coronary arteries. Vasodilation was observed on isolated working heart model as well, with elevated stroke volume in hearts treated with ERJ-500. Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion. Based on these observations it can be expected that our new hybrid ASA may contribute to new pharmacological tool in the therapy of ischemic heart conditions and associated syndromes.

AB - Ischemic heart conditions are among the main causes of sudden cardiac death worldwide. One of the strategies for avoiding myocardial infarction is the low-dose, prophylactic use of acetylsalicylic acid (ASA), an inhibitor of platelet aggregation. To avoid the gastrointestinal damage, ASA prodrugs bearing nitric oxide (NO)-donating moiety covalently conjugated to ASA have been synthesized and evaluated extensively worldwide. Herein the synthesis of a new hybrid ASA ester covalently attached to the NO donor linsidomine, an active metabolite of molsidomine (MOL) is reported. Cell viability assay and hemolysis tests were performed in H9c2 cells and rat erythrocytes, respectively. Our new compound, the ERJ-500 not affected negatively the viability of living cells in the concentration range of 100 nM to 100 μM. Using the ex vivo Langendorff method on hearts originated from female rats, compound ERJ-500 displayed a dose-dependent, outwashable vasodilative effect in coronary arteries. Vasodilation was observed on isolated working heart model as well, with elevated stroke volume in hearts treated with ERJ-500. Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion. Based on these observations it can be expected that our new hybrid ASA may contribute to new pharmacological tool in the therapy of ischemic heart conditions and associated syndromes.

KW - Acetylsalicylic acid

KW - Coronary flow

KW - Isolated heart

KW - Molsidomine

KW - Nitrogen oxide liberation

KW - Vasoactivity

UR - http://www.scopus.com/inward/record.url?scp=85061821522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061821522&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2019.02.020

DO - 10.1016/j.ejps.2019.02.020

M3 - Article

VL - 131

SP - 159

EP - 166

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -